BACKGROUND AND OBJECTIVES: Previous studies reported an association between metabolic syndrome , incident CKD, and proteinuria. This study examined the associations between metabolic syndrome and its components with ESRD and death among those patients with stages 3 and 4 CKD (estimated GFR=15-59 ml/min per 1.73 m(2)). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with stages 3 and 4 CKD (n=25,868) who had data relating to metabolic syndrome and were followed in our health care system were identified using an electronic medical record-based registry. Cox proportional hazards models and competing risk analyses were used to study the associations between metabolic syndrome, its components (elevated BP, low HDL cholesterol, elevated serum triglycerides, impaired glucose metabolism, and obesity), and all-cause mortality and ESRD while adjusting for demographics, comorbid conditions, use of relevant medications, and renal function. RESULTS: Sixty percent of the study population (n=15,605) had metabolic syndrome. In the multivariate-adjusted analysis, presence of metabolic syndrome was associated with an increased risk for ESRD (hazard ratio=1.33, 95% confidence interval=1.08, 1.64) but not death (hazard ratio=1.04, 95% confidence interval=0.97, 1.12) during a mean follow-up of 2.3 years. Among the individual components of metabolic syndrome, impaired glucose metabolism, elevated triglycerides, and hypertension were associated with increased risk for ESRD, whereas low HDL cholesterol and impaired glucose metabolism were associated with higher risk of death. CONCLUSIONS: Presence of metabolic syndrome is associated with ESRD but not death in patients with stages 3 and 4 CKD.
BACKGROUND AND OBJECTIVES: Previous studies reported an association between metabolic syndrome , incident CKD, and proteinuria. This study examined the associations between metabolic syndrome and its components with ESRD and death among those patients with stages 3 and 4 CKD (estimated GFR=15-59 ml/min per 1.73 m(2)). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with stages 3 and 4 CKD (n=25,868) who had data relating to metabolic syndrome and were followed in our health care system were identified using an electronic medical record-based registry. Cox proportional hazards models and competing risk analyses were used to study the associations between metabolic syndrome, its components (elevated BP, low HDL cholesterol, elevated serum triglycerides, impaired glucose metabolism, and obesity), and all-cause mortality and ESRD while adjusting for demographics, comorbid conditions, use of relevant medications, and renal function. RESULTS: Sixty percent of the study population (n=15,605) had metabolic syndrome. In the multivariate-adjusted analysis, presence of metabolic syndrome was associated with an increased risk for ESRD (hazard ratio=1.33, 95% confidence interval=1.08, 1.64) but not death (hazard ratio=1.04, 95% confidence interval=0.97, 1.12) during a mean follow-up of 2.3 years. Among the individual components of metabolic syndrome, impaired glucose metabolism, elevated triglycerides, and hypertension were associated with increased risk for ESRD, whereas low HDL cholesterol and impaired glucose metabolism were associated with higher risk of death. CONCLUSIONS: Presence of metabolic syndrome is associated with ESRD but not death in patients with stages 3 and 4 CKD.
Authors: C P Kovesdy; M E Czira; A Rudas; A Ujszaszi; L Rosivall; M Novak; K Kalantar-Zadeh; M Z Molnar; I Mucsi Journal: Am J Transplant Date: 2010-11-18 Impact factor: 8.086
Authors: Sankar D Navaneethan; Stacey E Jolly; Jesse D Schold; Susana Arrigain; Welf Saupe; John Sharp; Jennifer Lyons; James F Simon; Martin J Schreiber; Anil Jain; Joseph V Nally Journal: Clin J Am Soc Nephrol Date: 2010-11-04 Impact factor: 8.237
Authors: K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith Journal: Circulation Date: 2009-10-05 Impact factor: 29.690
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Stephen Zewinger; Thimoteus Speer; Marcus E Kleber; Hubert Scharnagl; Rainer Woitas; Philipp M Lepper; Karolin Pfahler; Sarah Seiler; Gunnar H Heine; Winfried März; Günther Silbernagel; Danilo Fliser Journal: J Am Soc Nephrol Date: 2014-03-07 Impact factor: 10.121
Authors: Sankar D Navaneethan; Jesse D Schold; Haiquan Huang; Georges Nakhoul; Stacey E Jolly; Susana Arrigain; Raed A Dweik; Joseph V Nally Journal: Am J Nephrol Date: 2016-02-19 Impact factor: 3.754
Authors: Sankar D Navaneethan; Jesse D Schold; Susana Arrigain; John P Kirwan; Joseph V Nally Journal: Kidney Int Date: 2016-01-12 Impact factor: 10.612
Authors: Mark D DeBoer; Stephanie L Filipp; Solomon K Musani; Mario Sims; Mark D Okusa; Matthew Gurka Journal: Kidney Blood Press Res Date: 2018-04-06 Impact factor: 2.687
Authors: Sankar D Navaneethan; Ciaran E Fealy; Amanda C Scelsi; Susana Arrigain; Steven K Malin; John P Kirwan Journal: Am J Nephrol Date: 2015-10-24 Impact factor: 3.754